14. Juli 2023 – Pfizer AG has submitted an application to Swissmedic, the Swiss Agency for Therapeutic Products, for authorisation of its updated monovalent COVID-19 vaccine. It encodes the spike protein for Omicron subvariant XBB.1.5 of SARS-CoV-2. Swissmedic is examining the application.

For more information, see here.